CN107746869A - 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途 - Google Patents

微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途 Download PDF

Info

Publication number
CN107746869A
CN107746869A CN201710860445.0A CN201710860445A CN107746869A CN 107746869 A CN107746869 A CN 107746869A CN 201710860445 A CN201710860445 A CN 201710860445A CN 107746869 A CN107746869 A CN 107746869A
Authority
CN
China
Prior art keywords
protein
ala
microalgal
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710860445.0A
Other languages
English (en)
Chinese (zh)
Inventor
A-C·V·贝恩
J·C·利普梅尔
K·E·埃普特
R·E·泽克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Vaccine Technologies SAS
Original Assignee
Sanofi Vaccine Technologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Vaccine Technologies SAS filed Critical Sanofi Vaccine Technologies SAS
Publication of CN107746869A publication Critical patent/CN107746869A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12—Unicellular algae; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201710860445.0A 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途 Pending CN107746869A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29044109P 2009-12-28 2009-12-28
US29046909P 2009-12-28 2009-12-28
US61/290,441 2009-12-28
US61/290,469 2009-12-28
US41335310P 2010-11-12 2010-11-12
US61/413,353 2010-11-12
CN201080064882.8A CN102822343B (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080064882.8A Division CN102822343B (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN107746869A true CN107746869A (zh) 2018-03-02

Family

ID=44307127

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080064882.8A Active CN102822343B (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途
CN201710860445.0A Pending CN107746869A (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201080064882.8A Active CN102822343B (zh) 2009-12-28 2010-12-28 微藻中异源多肽的生产，微藻胞外体、组合物及其制备方法和用途

Country Status (9)

Country Link
US (3) US20110189228A1 (enExample)
EP (3) EP4130273B1 (enExample)
JP (5) JP6339548B2 (enExample)
CN (2) CN102822343B (enExample)
AU (4) AU2010343095B2 (enExample)
CA (3) CA2785971C (enExample)
EA (1) EA022841B1 (enExample)
IN (1) IN2012DN06277A (enExample)
WO (1) WO2011090731A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109161576A (zh) * 2018-09-26 2019-01-08 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
CN111621471A (zh) * 2020-06-12 2020-09-04 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
CN112452506A (zh) * 2020-11-06 2021-03-09 五原县沃丰生物科技有限责任公司 一种培养基粉末的生产方法
CN114746553A (zh) * 2019-11-21 2022-07-12 松下知识产权经营株式会社 修饰蓝细菌、修饰蓝细菌的制造方法以及蛋白的制造方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI377253B (en) 2001-04-16 2012-11-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
TWI548648B (zh) 2009-03-16 2016-09-11 Ｄｓｍ智慧財產有限公司 於網黏菌門微生物中生產蛋白質之技術
MX351643B (es) * 2009-12-28 2017-10-23 Merial Ltd Antigeno ndv recombinante y usos del mismo.
CN103068984B (zh) * 2009-12-28 2017-12-01 Dsm Ip资产公司 微藻中血凝素‑神经氨酸酶蛋白的生产
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
CN107630017A (zh) 2011-03-07 2018-01-26 Dsm营养产品股份公司 工程化破囊壶菌属微生物
BR112014004188A2 (pt) 2011-08-24 2017-03-21 Novozymes Inc método para obter transformantes positivos de uma célula hospedeira fúngica filamentosa, célula hospedeira fúngica filamentosa, método para produzir múltiplos polipeptídeos recombinantes, e, construto em tandem
US9982249B2 (en) 2012-07-24 2018-05-29 Bp Corporation North America Inc. Xylose isomerases and their uses
US20150232900A1 (en) * 2012-09-18 2015-08-20 Myko Tech Private Limited Paper folding method and device for manufacturing filter cartridges
BR112017006833B1 (pt) 2014-10-02 2022-09-13 Evonik Operations Gmbh Alimento para animais contendo ácido graxo poli-insaturado e processo para produzir o mesmo
US11324234B2 (en) 2014-10-02 2022-05-10 Evonik Operations Gmbh Method for raising animals
ES2870093T3 (es) 2014-10-02 2021-10-26 Evonik Operations Gmbh Biomasa que contiene PUFA con estabilidad celular elevada y su empleo para la producción de piensos
BR112017006834B1 (pt) * 2014-10-02 2022-04-26 Evonik Operations Gmbh Processo para a preparação de um alimento para animais compreendendo pufas, produto extrudado de alimento para animais e método de criação de animais
WO2016140925A1 (en) 2015-03-02 2016-09-09 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
HK1254383A1 (zh) 2015-07-13 2019-07-19 MARA Renewables Corporation 增强木糖的微藻代谢
FR3038913B1 (fr) * 2015-07-17 2020-05-01 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
CN109890964A (zh) * 2016-09-09 2019-06-14 康奈尔大学 核酸、蛋白和小分子在玻璃体囊泡体中的递送
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
WO2018098001A1 (en) * 2016-11-27 2018-05-31 Triton Algae Innovations, Inc. Method of purification of recombinant osteopontin from microalgae
WO2019173226A1 (en) * 2018-03-05 2019-09-12 Synthetic Genomics, Inc. Organisms and methods for producing glycomolecules with low sulfation
EP3817519A4 (en) 2018-06-27 2022-03-23 Sumitomo Electric Industries, Ltd. ORIGINAL FORM BODY OF FLEXIBLE PRINTED CIRCUIT BOARD, METHOD FOR MANUFACTURING FLEXIBLE PRINTED CIRCUIT BOARD, FOCUSED PHOTOVOLTAIC ENERGY GENERATING MODULE AND ELECTROLUMINESCENT MODULE
WO2020061550A1 (en) 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
IT201900024580A1 (it) 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN111363045B (zh) * 2020-02-18 2021-12-17 厦门大学 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法
JP2021186420A (ja) * 2020-06-03 2021-12-13 株式会社三洋物産 遊技機
JP2022028997A (ja) * 2020-07-31 2022-02-17 株式会社三洋物産 遊技機
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
WO2022269557A1 (en) * 2021-06-24 2022-12-29 Reliance Industries Limited Recombinant algae and production of spider silk protein from the recombinant algae
CN113698451B (zh) * 2021-08-02 2023-04-11 广东海洋大学 一种微藻多肽及其制备方法和应用
KR20240105412A (ko) 2021-11-05 2024-07-05 사노피 파스퇴르 인크 재조합 헤마글루티닌과 뉴라미니다제를 포함하는 다가 인플루엔자 백신 및 이의 사용 방법
JP2024540290A (ja) 2021-11-05 2024-10-31 サノフイ ヘマグルチニン及びノイラミニダーゼを含むハイブリッド多価インフルエンザワクチン及びそれを使用する方法
CA3239417A1 (en) 2021-11-30 2023-06-08 Yvonne CHAN Human metapneumovirus vaccines
WO2023232976A1 (en) * 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
CA3258773A1 (en) 2022-06-14 2023-12-21 Semmelweis Egyetem EXTRACELLULAR VESICLES INTENDED FOR USE IN THERAPY
CN115992052A (zh) * 2022-11-18 2023-04-21 暨南大学 一种微藻类外泌体、其制备方法和应用
JP7546136B1 (ja) 2023-12-27 2024-09-05 ロート製薬株式会社 微細藻類由来の細胞外小胞を含有する組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824309A (en) * 1995-12-05 1998-10-20 University Of Massachusetts Recombinant gas vesicles and uses thereof
CN1354792A (zh) * 1999-05-28 2002-06-19 爱尔基因泰克株式会社 用转化的微藻生物合成外源蛋白质
CN1556850A (zh) * 2001-04-16 2004-12-22 ��̩�������ѧ��˾ 转化破囊壶菌目微生物的产物和方法
CN101484466A (zh) * 2006-02-16 2009-07-15 美国国有健康与人类服务部(马里兰州) 针对流感病毒的抗病毒剂和疫苗
WO2009101160A1 (en) * 2008-02-12 2009-08-20 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Production of glycosylated polypeptides in microalgae

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
CA2180965C (en) * 1994-01-11 2010-05-11 Tom Maria Deroo Influenza vaccine
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
MXPA02012254A (es) * 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
US7029872B2 (en) * 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US20060257399A1 (en) 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
AU2007249124B2 (en) * 2001-04-16 2012-05-17 Dsm Ip Assets B.V. Product and process for transformation of thraustochytriales microorganisms
AU2003217413A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
EP1494708A1 (en) * 2002-04-12 2005-01-12 Capua, Ilaria Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
WO2005016961A1 (en) * 2003-06-05 2005-02-24 Wyeth Holdings Corporation Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
AU2005248375B2 (en) * 2004-05-25 2010-12-16 Medimmune, Llc Influenza hemagglutinin and neuraminidase varians
US8936930B2 (en) * 2004-08-05 2015-01-20 Ben-Gurion University Of The Negev Research And Development Authority Red microalgae expressing exogenous polypeptides and methods of generating and utilizing same
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
JP4796787B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
JP4796786B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類を形質転換可能なベクター
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
AU2006279323B2 (en) * 2005-08-16 2013-08-01 Merck Sharp & Dohme Corp. Influenza recombinant subunit vaccine
US20070224205A1 (en) * 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
TW200813222A (en) * 2006-03-15 2008-03-16 Martek Biosciences Corp Polyunsaturated fatty acid production in heterologous organisms using PUFA polyketide synthase systems
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2238253B1 (en) * 2007-11-27 2012-09-12 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
KR20090096890A (ko) * 2008-03-10 2009-09-15 전남대학교산학협력단 대장균에서 조류인플루엔자 바이러스의 뉴라미니다제 ｎ1을발현하기 위한 벡터 및 방법, 이의 사용방법, 및뉴라미니다제 저해제
FR2928926B1 (fr) * 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
CN101990524A (zh) * 2008-03-19 2011-03-23 禾逊专业化学公司 用于混凝土和水泥配制剂的改性剂及其制备方法
TWI548648B (zh) * 2009-03-16 2016-09-11 Ｄｓｍ智慧財產有限公司 於網黏菌門微生物中生產蛋白質之技術
MX351643B (es) * 2009-12-28 2017-10-23 Merial Ltd Antigeno ndv recombinante y usos del mismo.
CN103068984B (zh) * 2009-12-28 2017-12-01 Dsm Ip资产公司 微藻中血凝素‑神经氨酸酶蛋白的生产

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824309A (en) * 1995-12-05 1998-10-20 University Of Massachusetts Recombinant gas vesicles and uses thereof
CN1354792A (zh) * 1999-05-28 2002-06-19 爱尔基因泰克株式会社 用转化的微藻生物合成外源蛋白质
CN1556850A (zh) * 2001-04-16 2004-12-22 ��̩�������ѧ��˾ 转化破囊壶菌目微生物的产物和方法
CN101484466A (zh) * 2006-02-16 2009-07-15 美国国有健康与人类服务部(马里兰州) 针对流感病毒的抗病毒剂和疫苗
WO2009101160A1 (en) * 2008-02-12 2009-08-20 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Production of glycosylated polypeptides in microalgae

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GIUSEPPINA TURTURICI等: "Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages", 《AM J PHYSIOL CELL PHYSIOL》 *
MARKUS FUHRMANN: ""Production of Antigens in Chlamydomonas reinhardtii：Green Microalgae as a Novel Source of Recombinant Proteins"", 《METHODS IN MOLECULAR MEDICINE》 *
OLIVIER GASSER等: "Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils", 《EXPERIMENTAL CELL RESEARCH》 *
TARA L.等: ""Microalgae as bioreactors"", 《PLANT CELL REP》 *
YOKO SHOJI等: ""Plant-expressed HA as a seasonal influenza vaccine candidate"", 《VACCINE》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109161576A (zh) * 2018-09-26 2019-01-08 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
CN114746553A (zh) * 2019-11-21 2022-07-12 松下知识产权经营株式会社 修饰蓝细菌、修饰蓝细菌的制造方法以及蛋白的制造方法
CN111621471A (zh) * 2020-06-12 2020-09-04 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
CN111621471B (zh) * 2020-06-12 2022-03-11 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
CN112452506A (zh) * 2020-11-06 2021-03-09 五原县沃丰生物科技有限责任公司 一种培养基粉末的生产方法

Also Published As

Publication number Publication date
JP7745996B2 (ja) 2025-09-30
EP3505632A1 (en) 2019-07-03
EP3505632B1 (en) 2022-08-03
IN2012DN06277A (enExample) 2015-09-25
JP6339548B2 (ja) 2018-06-06
US20110189228A1 (en) 2011-08-04
CN102822343A (zh) 2012-12-12
JP7585382B2 (ja) 2024-11-18
AU2010343095B2 (en) 2017-01-05
CA3028175C (en) 2022-05-24
EP2519635A4 (en) 2013-06-26
JP6666950B2 (ja) 2020-03-18
JP2016047055A (ja) 2016-04-07
EP4130273A1 (en) 2023-02-08
CA2785971A1 (en) 2011-07-28
CN102822343B (zh) 2017-10-20
AU2019206054B2 (en) 2022-03-10
JP2020096635A (ja) 2020-06-25
WO2011090731A1 (en) 2011-07-28
US20200063174A1 (en) 2020-02-27
AU2017202195B2 (en) 2019-04-18
AU2019206054A1 (en) 2019-08-08
US20150110826A1 (en) 2015-04-23
AU2022203980A1 (en) 2022-06-30
CA2785971C (en) 2019-02-12
JP2023101420A (ja) 2023-07-20
AU2017202195A1 (en) 2017-04-20
EP4130273B1 (en) 2024-06-12
EP2519635A1 (en) 2012-11-07
EA201290567A1 (ru) 2013-02-28
AU2022203980B2 (en) 2024-12-12
EA022841B1 (ru) 2016-03-31
JP2025114812A (ja) 2025-08-05
JP2018121660A (ja) 2018-08-09
CA3028175A1 (en) 2011-07-28
EP4130273C0 (en) 2024-06-12
CA3153553A1 (en) 2011-07-28
JP5838496B2 (ja) 2016-01-06
EP2519635B1 (en) 2018-11-21
JP2013515503A (ja) 2013-05-09
AU2010343095A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
JP7585382B2 (ja) 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
CN110656123B (zh) 基于CRISPR-Cas13d系统的sgRNA高效作用靶点的筛选方法及应用
RU2766680C1 (ru) Новые варианты гиалуронидазы и содержащая их фармацевтическая композиция
CN110029096B (zh) 一种腺嘌呤碱基编辑工具及其用途
KR101939014B1 (ko) 라비린툴로바이코타문 미생물에서의 단백질 생산
KR102863167B1 (ko) 클로스트리듐 박테리아의 형질전환을 위한 유전자 도구
KR102092422B1 (ko) 유전자 조작된 미생물로부터 뮤콘산의 생산
US6773920B1 (en) Delivery of functional protein sequences by translocating polypeptides
KR20210139265A (ko) 표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기 및 이의 사용 방법
KR20210125560A (ko) 유전성 질환의 치료를 위한 것을 포함하는, 아데노신 데아미나제 염기 편집기를 사용한 질환-관련 유전자의 스플라이스 수용체 부위 파괴
KR20210124280A (ko) 표적-이탈 탈아미노화가 감소된 핵염기 편집기 및 이를 이용하여 핵염기 표적 서열을 변형시키는 방법
CN112680434B (zh) 一种提高蛋白质谷氨酰胺酶分泌表达的方法
KR20210127206A (ko) 유전성 질환의 치료를 위한 것을 포함하는, 아데노신 데아미나제 염기 편집기를 사용하여 질환-관련 유전자를 편집하는 방법
KR102823029B1 (ko) 알파바이러스 레플리콘 입자
DK2713712T3 (en) TRANSGEN CHICKEN, INCLUDING AN INACTIVATED IMMUNGLOBULIN GENE
CN107858297A (zh) 在蔗糖上生长的重组破囊壶菌和其组合物、制备方法及用途
KR20240005196A (ko) 유전자 조작된 미생물로부터 개선된 뮤콘산 생산
CN114836443B (zh) 重组柯萨奇病毒a10 vlp及其用途
CN112996536B (zh) 具有异源刺突蛋白的h52 ibv疫苗
CN113186140B (zh) 用于预防和/或治疗宿醉和肝病的基因工程细菌
KR20230157342A (ko) 다중 치환기 실로시빈 유도체 및 사용 방법
KR102335519B1 (ko) 인체 감염 사스코로나 바이러스 예방 및 감염 증상 완화용 백신 조성물
KR20180038462A (ko) 재조합 세포, 재조합 세포의 제조 방법, 및 1,4-부탄디올의 생산 방법
RU2795596C2 (ru) Частица репликона альфавируса
CN113151311A (zh) 一种表达hpv 59l1的多核苷酸及其表达载体、宿主细胞和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination